Genomics is underpinning a global revolution in healthcare, from a generalized approach, to one that is individually tailored based on a patient’s genetic profile – an approach known as precision medicine. Rapid advances in the field – and the opportunities for discovery and new therapeutics – make it imperative to develop international policies and standards to enable the responsible, voluntary, and secure sharing of genomic data.
Genome Canada congratulates Dr. Mona Nemer on her appointment as Canada’s new Chief Science Advisor and applauds the Government of Canada on its excellent choice.
Dr. Nemer’s deep commitment to Canada’s research community, both as a renowned scientist and as an esteemed university vice-president of research, are widely recognized and celebrated here in Canada and abroad.
Genome Canada is delighted to welcome Rob Annan as Vice-President, Public Affairs and Communications, effective September 11, 2017.
In this role, Dr. Annan will drive an overarching strategy that promotes the value and potential of genomics in Canada to Genome Canada’s major stakeholders, while raising the public profile of Genome Canada both nationally and internationally.
Genome Canada is pleased to release its Annual Report 2016-17, Partnership – It’s In Our DNA.
Montreal scientists and their international colleagues have closed in on specific genes responsible for Inflammatory Bowel Disease (IBD) from a list of over 600 genes that were suspects for the disease. Professor John D.
Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins.
They have also identified two distinct stem-cell like populations from which relapse can arise in different patients in this aggressive cancer that they previously showed starts in blood stem cells in the bone marrow.